Placebo to Remibrutinib (LOU064) 0 mg matching 00 mg film-coated tablet, TRIAMCINOLONE , Placebo to Remibrutinib (LOU064) 0 mg matching 00 mg film-coated tablet, LOU064, CLINDAMYCIN , LOU064, -
CLOU064J12301
Phase 3 small_molecule active
Quick answer
Placebo to Remibrutinib (LOU064) 0 mg matching 00 mg film-coated tablet, TRIAMCINOLONE , Placebo to Remibrutinib (LOU064) 0 mg matching 00 mg film-coated tablet, LOU064, CLINDAMYCIN , LOU064, - for Hidradenitis Suppurativa (HS) is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Hidradenitis Suppurativa (HS)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active